Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors.
AIM
The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors.


PATIENTS AND METHODS
Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR).


RESULTS
Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098).


CONCLUSION
The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.
['Chrom|Pawel|P|', 'Stec|Rafal|R|', 'Bodnar|Lubomir|L|', 'Szczylik|Cezary|C|']
D000328:Adult D000368:Aged D002292:Carcinoma, Renal Cell D005260:Female D006801:Humans D007680:Kidney Neoplasms D008297:Male D008875:Middle Aged D010190:Pancreatic Neoplasms D011379:Prognosis D047428:Protein Kinase Inhibitors D011505:Protein-Tyrosine Kinases D012189:Retrospective Studies D016019:Survival Analysis
pancreatic metastases tyrosine kinase inhibitor overall survival prognostic factor Metastatic renal cell carcinoma